{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:31:15Z","timestamp":1794346275487,"version":"4.9.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2022R1A6C101A739"],"award-info":[{"award-number":["2022R1A6C101A739"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2021R1A2C1012421"],"award-info":[{"award-number":["2021R1A2C1012421"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2021R1A4A3031661"],"award-info":[{"award-number":["2021R1A4A3031661"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2021R1C1C1004023"],"award-info":[{"award-number":["2021R1C1C1004023"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003716","name":"Korea Basic Science Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.biopha.2023.115587","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T17:02:22Z","timestamp":1695834142000},"page":"115587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease"],"prefix":"10.1016","volume":"167","author":[{"given":"Dong-Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4604-1256","authenticated-orcid":false,"given":"JinJoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2890-3864","authenticated-orcid":false,"given":"Susan","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaekyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yewon","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Mi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Goo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hoon","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1868-4784","authenticated-orcid":false,"given":"Yong-Hyun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115587_bib1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2023.115587_bib2","first-page":"293","article-title":"Primary sclerosing cholangitis, part 1: epidemiology, etiopathogenesis, clinical features, and treatment","volume":"14","author":"Tabibian","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2023.115587_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrgastro.2016.154","article-title":"Genetics of primary sclerosing cholangitis and pathophysiological implications","volume":"14","author":"Jiang","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2023.115587_bib4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/hep.31067","article-title":"The spectrum of reactive cholangiocytes in primary sclerosing cholangitis","volume":"71","author":"Guicciardi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2023.115587_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03299-5","article-title":"Paracrine cellular senescence exacerbates biliary injury and impairs regeneration","volume":"9","author":"Ferreira-Gonzalez","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.115587_bib6","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1073\/pnas.92.12.5545","article-title":"Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism","volume":"92","author":"Datto","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2023.115587_bib7","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.3390\/cells10102618","article-title":"Bile acids activate NLRP3 inflammasome, promoting murine liver inflammation or fibrosis in a cell type-specific manner","volume":"10","author":"Holtmann","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2023.115587_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155781","article-title":"Balance between interleukin-18 and Interleukin-18 binding protein in auto-inflammatory diseases","volume":"150","author":"Harel","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2023.115587_bib9","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3390\/biomedicines10071750","article-title":"Interleukin-18 binding protein in immune regulation and autoimmune diseases","volume":"10","author":"Park","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2023.115587_bib10","article-title":"Albumin-binding recombinant human IL-18BP ameliorates macrophage activation syndrome and atopic dermatitis via direct IL-18 inactivation","author":"Jang","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2023.115587_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0009-8981(03)00336-X","article-title":"The effect of endoscopic retrograde cholangiopancreatography on the serum IL-18 and erythrocytes antioxidative capacity in biliary obstructive jaundice","volume":"336","author":"El-Sayed","year":"2003","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.biopha.2023.115587_bib12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ajpath.2016.10.010","article-title":"Nlrp3 activation induces Il-18 synthesis and affects the epithelial barrier function in reactive cholangiocytes","volume":"187","author":"Maroni","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2023.115587_bib13","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.4049\/jimmunol.167.10.5913","article-title":"IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas\/Fas ligand-mediated models of liver disease in mice","volume":"167","author":"Faggioni","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2023.115587_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108756","article-title":"Interleukin-18 promotes fibroblast senescence in pulmonary fibrosis through down-regulating Klotho expression","volume":"113","author":"Zhang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.115587_bib15","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1084\/jem.20190669","article-title":"Inherited IL-18BP deficiency in human fulminant viral hepatitis","volume":"216","author":"Belkaya","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2023.115587_bib16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/cyto.2001.0914","article-title":"A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18","volume":"14","author":"Novick","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2023.115587_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.803098","article-title":"Biliary epithelial senescence in liver disease: there will be SASP","volume":"8","author":"Meadows","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biopha.2023.115587_bib18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41575-019-0125-y","article-title":"Cholangiocyte pathobiology","volume":"16","author":"Banales","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2023.115587_bib19","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1136\/gutjnl-2018-316670","article-title":"Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis","volume":"68","author":"Liao","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2023.115587_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.intimp.2019.02.016","article-title":"The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice","volume":"70","author":"Qu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2023.115587_bib21","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20200689","article-title":"NLRP3 receptor contributes to protection against experimental antigen-mediated cholangitis","volume":"40","author":"Gonz\u00e1lez","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.biopha.2023.115587_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4254\/wjh.v8.i8.401","article-title":"Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-\/-) mouse model","volume":"8","author":"Reiter","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.biopha.2023.115587_bib23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nm1415","article-title":"Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance","volume":"12","author":"Netea","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2023.115587_bib24","article-title":"Differential IL18 signaling via IL18 receptor and Na-Cl co-transporter discriminating thermogenesis and glucose metabolism regulation","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.115587_bib25","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.celrep.2019.10.042","article-title":"Intestinal IL-17R signaling constrains IL-18-driven liver inflammation by the regulation of microbiome-derived products","volume":"29","author":"Cruz","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2023.115587_bib26","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.4049\/jimmunol.162.11.6829","article-title":"IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells","volume":"162","author":"Pizarro","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2023.115587_bib27","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.cell.2015.10.072","article-title":"Epithelial IL-18 equilibrium controls barrier function in colitis","volume":"163","author":"Nowarski","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2023.115587_bib28","article-title":"Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis","volume":"3","author":"Cazzagon","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.biopha.2023.115587_bib29","article-title":"Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2 (-\/-) mouse","volume":"3","author":"Alsuraih","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.biopha.2023.115587_bib30","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.32776","article-title":"Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis","volume":"77","author":"Knorr","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2023.115587_bib31","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2023.115587_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile acids as hormones: the FXR-FGF15\/19 pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig. Dis."},{"key":"10.1016\/j.biopha.2023.115587_bib33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2023.115587_bib34","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2023.115587_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J. Hepatol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223013859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223013859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T21:28:22Z","timestamp":1776461302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223013859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":35,"alternative-id":["S0753332223013859"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115587","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115587"}}